2024-519010-31-00RecruitingPhase 1
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT
Fondazione Melanoma Onlus8 sites in 1 country80 target enrollmentStarted: September 15, 2025Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 80
- Locations
- 8
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Medical Monitor
Scientific
Fondazione Melanoma Onlus
Study Sites (8)
Loading locations...
Similar Trials
Completed
Phase 1
A single-centre, open-label, phase I trial evaluating the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volunteers2024-515124-36-00Integrative Research Laboratories Sweden AB12
Recruiting
Phase 1
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.2023-510356-23-00Novartis Pharma AG76
Active, not recruiting
Phase 1
An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors2024-513716-95-00Nec Oncoimmunity AS6
Completed
Phase 2
A study to test whether BI 706321 combined with ustekinumab helps people with Crohn's Disease2024-512756-38-00Boehringer Ingelheim International GmbH27
Recruiting
Phase 1
A prospective, single-center phase I pilot study to assess the tissue activity of multidrug resistance-associated protein 1 with positron emission tomography2024-517851-11-00Medical University Of Vienna40